search
Back to results

Sleep and Cardiovascular Health in Adolescence

Primary Purpose

Insomnia Type; Sleep Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
No pre-sleep arousal manipulation
pre-sleep arousal down-regulation
pre-sleep arousal up-regulation
Sponsored by
SRI International
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Insomnia Type; Sleep Disorder focused on measuring Cardiovascular, Blood Pressure, ECG, EEG

Eligibility Criteria

16 Years - 20 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Must be post-pubertal
  • BMI <30 kg/m-2 to reduce the likelihood of obesity-related sleep-disordered breathing

Exclusion Criteria:

  • Current use of drugs known to affect sleep and CV systems (e.g., Antidepressants, stimulants, beta-blockers)
  • Serious history of, or current medical conditions that could affect brain function, or study participation, including Diabetes, cancer, neurological diseases (e.g., Seizure disorders) recurrent migraine, cardiovascular diseases (e.g., Hypertension) and traumatic brain injury with loss of consciousness >30 minutes
  • Current DSM-5 diagnosis of Neurodevelopmental Disorders (e.g., Attention-Deficit/Hyperactivity Disorder)
  • Current DSM-5 diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders
  • Current DSM-5 diagnosis of Depressive and Anxiety Disorders (e.g., Major Depressive Disorder)
  • Current DSM-5 diagnosis of Post-Traumatic Stress Disorder
  • Current DSM-5 diagnosis of Substance-Related and Addictive Disorders (e.g., Alcohol Use Disorder)
  • History of and persistence in severe learning disorder, pervasive developmental disorder, or other condition requiring repeated or persistent specialized education (e.g., Estimated intellectual quotient (IQ) >2 standard deviations below mean)
  • Current psychiatric disorders in both control and insomnia groups is exclusionary
  • Past history of psychiatric disorders in controls is exclusionary (past history of psychiatric disorders in the insomnia group is not exclusionary)
  • Shift work in the previous year and no time-zone travel in the past month
  • Evidence of other DSM-5 Sleep-Wake Disorders (e.g., Narcolepsy), Breathing-Related Sleep Disorders (e.g., Obstructive Sleep Apnea Hypopnea, Circadian Rhythm Sleep-Wake Disorders and particularly Delayed Sleep Phase Type), and Parasomnias (e.g., Non-Rapid Eye Movement Sleep Arousal Disorders, Rapid Eye Movement Sleep Behavior Disorder and Restless Legs Syndrome)
  • Current pregnancy

Sites / Locations

  • SRI International

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Non-insomnia Group

Insomnia Group

Arm Description

Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia. Interventions (order is randomly assigned): no pre-sleep arousal manipulation night; pre-sleep arousal down-regulation night pre-sleep arousal up-regulation night.

Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder. Interventions (order is randomly assigned): no pre-sleep arousal manipulation night; pre-sleep arousal down-regulation night pre-sleep arousal up-regulation night.

Outcomes

Primary Outcome Measures

Average nocturnal heart rate (HR), as a measure of cardiac contractility
Heart rate (HR) response to experimental manipulation
Average nocturnal Pre-ejection period (PEP), as a measure of cardiac sympathetic activity
Pre-ejection period (PEP) response to experimental manipulation

Secondary Outcome Measures

Full Information

First Posted
October 25, 2018
Last Updated
April 27, 2023
Sponsor
SRI International
search

1. Study Identification

Unique Protocol Identification Number
NCT03727906
Brief Title
Sleep and Cardiovascular Health in Adolescence
Official Title
Sleep and Cardiovascular Health in Adolescence
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
January 7, 2019 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
August 27, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
SRI International

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Insomnia is a prevalent and under-recognized disorder in adolescence, particularly in girls, with long-term repercussions for mental and physical health. This study assesses manifestation of autonomic hyperarousal and vulnerability to insomnia using a sample of male and female adolescents with and without Diagnostic and Statistical Manual (DSM-5) Insomnia Disorder. Outcomes from this study have the potential to inform prevention and treatment interventions for insomnia that can be implemented at a young age before chronic negative sequelae of this common disorder manifest.
Detailed Description
Insomnia is highly prevalent in adolescence, particularly in post-pubertal girls and tends to persist over time. Insomnia is considered a hyperarousal disorder, in which abnormally elevated levels of cognitive and physiological activation, particularly evident at bed-time, prevent individuals from falling asleep and having a restorative night's sleep. Hyperarousal is a major pathophysiological mechanism linking insomnia with poor mental and physical health, including cardiovascular (CV) disease. The investigators and others have shown evidence of autonomic nervous system (ANS) dysfunction such as hyperactivation of the sympathetic branch of the ANS - a major etiological factor in CV disease - in young and midlife adults, both before and during sleep. It is unknown if ANS hyperarousal is evident in adolescents with insomnia. The biological basis for an emerging sex difference in insomnia prevalence in adolescence is unknown. The investigators' pilot data reveal intriguing evidence of sex-differences in basic and stress-dependent ANS modulation during sleep in adolescents with girls showing a greater ANS response to stress. These data suggest the existence of a predisposing and stress-dependent ANS vulnerability in female adolescents, a potential pathway to develop insomnia. This study takes a novel approach to investigating the manifestation of physiological ANS and CV hyperarousal in adolescents with insomnia by experimentally manipulating the pre-sleep arousal state via stress-induced ANS up-regulation and relaxation-driven ANS down-regulation. In addition, the study focuses on sex differences in ANS and CV responses to pre-sleep ANS manipulation, potentially addressing the question of why female sex is a major risk factor for insomnia. The investigators aim to test 110 male and female high-school students (16-20y) with and without DSM-5 Insomnia Disorder, during a regular in-lab polysomnographic night (baseline) and under experimental pre-sleep stress (psychosocial stressor) and pre-sleep relaxation (Virtual reality ANS bio-feedback) intervention nights, using state-of-the-art, noninvasive, beat-to-beat ANS and CV measures, including blood pressure, to assess nocturnal ANS and CV function in adolescents with insomnia (Aim 1); the impact of pre-sleep ANS arousal levels on nocturnal ANS and CV function, and sleep in adolescents with and without insomnia, considering possible sex differences (Aim 2), and the extent to which nocturnal ANS and CV function mediate the effect of pre-sleep arousal levels on objective and perceived sleep quality (Aim 3). This study has the potential to elucidate pathophysiological ANS hyperarousal underlying Insomnia Disorder in adolescence, including potential reasons for the vulnerability to insomnia in girls, leading to better recognition and potentially new treatment strategies of this disorder targeted at the state of ANS hyperarousal in the pre-sleep period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insomnia Type; Sleep Disorder
Keywords
Cardiovascular, Blood Pressure, ECG, EEG

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
The experimental paradigm will consist of three in-lab counterbalanced non-consecutive (≥2 days in-between) polysomnography (PSG) nights in which we will modulate the level of pre-sleep psychophysiological arousal in a group of insomnia and non-insomnia adolescents. no pre-sleep arousal manipulation night; pre-sleep arousal down-regulation night (pre-sleep relaxation-driven Virtual reality ANS downregulation); pre-sleep arousal up-regulation night (pre-sleep anticipation of stress using the Trier Social StressTest).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
115 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Non-insomnia Group
Arm Type
Other
Arm Description
Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia. Interventions (order is randomly assigned): no pre-sleep arousal manipulation night; pre-sleep arousal down-regulation night pre-sleep arousal up-regulation night.
Arm Title
Insomnia Group
Arm Type
Other
Arm Description
Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder. Interventions (order is randomly assigned): no pre-sleep arousal manipulation night; pre-sleep arousal down-regulation night pre-sleep arousal up-regulation night.
Intervention Type
Other
Intervention Name(s)
No pre-sleep arousal manipulation
Other Intervention Name(s)
Baseline
Intervention Description
As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
Intervention Type
Other
Intervention Name(s)
pre-sleep arousal down-regulation
Other Intervention Name(s)
pre-sleep relaxation
Intervention Description
On the "low pre-sleep arousal night", about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process.
Intervention Type
Other
Intervention Name(s)
pre-sleep arousal up-regulation
Other Intervention Name(s)
pre-sleep stress
Intervention Description
On the "high pre-sleep arousal" night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone).
Primary Outcome Measure Information:
Title
Average nocturnal heart rate (HR), as a measure of cardiac contractility
Description
Heart rate (HR) response to experimental manipulation
Time Frame
Measured during 1 night (each for baseline, pre-sleep stress and pre-sleep relaxation conditions)
Title
Average nocturnal Pre-ejection period (PEP), as a measure of cardiac sympathetic activity
Description
Pre-ejection period (PEP) response to experimental manipulation
Time Frame
Measured during 1 night (each for baseline, pre-sleep stress and pre-sleep relaxation conditions)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Must be post-pubertal BMI <30 kg/m-2 to reduce the likelihood of obesity-related sleep-disordered breathing Exclusion Criteria: Current use of drugs known to affect sleep and CV systems (e.g., Antidepressants, stimulants, beta-blockers) Serious history of, or current medical conditions that could affect brain function, or study participation, including Diabetes, cancer, neurological diseases (e.g., Seizure disorders) recurrent migraine, cardiovascular diseases (e.g., Hypertension) and traumatic brain injury with loss of consciousness >30 minutes Current DSM-5 diagnosis of Neurodevelopmental Disorders (e.g., Attention-Deficit/Hyperactivity Disorder) Current DSM-5 diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders, Bipolar and Related Disorders Current DSM-5 diagnosis of Depressive and Anxiety Disorders (e.g., Major Depressive Disorder) Current DSM-5 diagnosis of Post-Traumatic Stress Disorder Current DSM-5 diagnosis of Substance-Related and Addictive Disorders (e.g., Alcohol Use Disorder) History of and persistence in severe learning disorder, pervasive developmental disorder, or other condition requiring repeated or persistent specialized education (e.g., Estimated intellectual quotient (IQ) >2 standard deviations below mean) Current psychiatric disorders in both control and insomnia groups is exclusionary Past history of psychiatric disorders in controls is exclusionary (past history of psychiatric disorders in the insomnia group is not exclusionary) Shift work in the previous year and no time-zone travel in the past month Evidence of other DSM-5 Sleep-Wake Disorders (e.g., Narcolepsy), Breathing-Related Sleep Disorders (e.g., Obstructive Sleep Apnea Hypopnea, Circadian Rhythm Sleep-Wake Disorders and particularly Delayed Sleep Phase Type), and Parasomnias (e.g., Non-Rapid Eye Movement Sleep Arousal Disorders, Rapid Eye Movement Sleep Behavior Disorder and Restless Legs Syndrome) Current pregnancy
Facility Information:
Facility Name
SRI International
City
Menlo Park
State/Province
California
ZIP/Postal Code
94025
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Sleep and Cardiovascular Health in Adolescence

We'll reach out to this number within 24 hrs